Evidence map›Paper›PMID 31585957›Full record

ArticleBMJ case reports2019

Rare basal cell metastasis of a basal-squamous skin collision tumour to the lung and axillary lymph node.

Rui Li, Gina Lee, Min Huang, Ahmed El-Sherief

Registry-linked trialOpen access · bronzeAbstract readCase Reports
In one paragraph

Article in BMJ case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03132636 (A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03132636 phase2completednot on this map

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1, in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy

TypeinterventionalSponsorRegeneron PharmaceuticalsRan2017 to 2023Enrolled138ConditionsCarcinoma, Basal CellArmscemiplimab
3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Rui LiPulmonary and Critical Care, UCLA, Los Angeles, California, USA.
Gina LeePulmonary and Critical Care, UCLA, Los Angeles, California, USA gina.lee@va.gov.ORCID http://orcid.org/0000-0002-0628-6930
Min HuangPathology, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, California, USA.
Ahmed El-SheriefRadiology, UCLA, Los Angeles, California, USA.
Pulmonary and Critical Care Associates · USVA Greater Los Angeles Healthcare System · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report a case of a 60-year-old man who was a former cigar smoker with a slow-growing, large exophytic left shoulder mass (15 cm in diameter) and later found to have left axillary lymphadenopathy. Fine needle aspirate biopsy of the left shoulder mass revealed squamous cell carcinoma (SCC). However, pathology of the enlarged left axillary lymph node was reported as metastatic adenocarcinoma. The patient underwent surgical resection of the shoulder mass which comprised of SCC (>95%) and adenoid basal cell carcinoma (BCC) as a second component of the tumour. The BCC had identical histology as the metastatic carcinoma in the left axillary lymph node. Therefore, diagnosis was revised as cutaneous collision tumour with metastatic BCC. Six months later following adjuvant radiation therapy, the patient was diagnosed with metastatic BCC in the right lung. Stereotactic body radiation therapy (SBRT) and a selective hedgehog pathway inhibitor vismodegib were given with only limited efficacy. Clinical trial registration number NCT03132636.

Indexed as

AnilidesAxillaBasal Cell CarcinomaCarcinoma, Squamous CellHedgehog ProteinsHumansLung NeoplasmsLymph NodesMaleMiddle AgedPyridinesRadiosurgeryRadiotherapy, AdjuvantSkin NeoplasmsTreatment OutcomeAnilidesHedgehog ProteinsHhAntag691Pyridineslung cancer (oncology)skin cancer

Identifiers

PMID31585957
PMCPMC6782041
OpenAlexW2978293178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.